These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8822081)

  • 1. Octreotide therapy in carcinoid disease.
    Bax ND; Woods HF; Batchelor A; Jennings M
    Anticancer Drugs; 1996 Jan; 7 Suppl 1():17-22. PubMed ID: 8822081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinoid of the pancreas.
    Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
    Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
    O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
    Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
    Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A
    Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
    Gardner-Roehnelt NM
    Clin J Oncol Nurs; 2012 Feb; 16(1):56-64. PubMed ID: 22297008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting formulations of somatostatin analogues.
    Anthony LB
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinoid tumor and intravenous octreotide infusion during labor and delivery.
    Le BT; Bharadwaj S; Malinow AM
    Int J Obstet Anesth; 2009 Apr; 18(2):182-5. PubMed ID: 19200714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumour vanishes.
    Todd JF; Meeran K
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):663-4. PubMed ID: 11155085
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
    Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
    Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
    Tomassetti P; Migliori M; Corinaldesi R; Gullo L
    Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide.
    Lamberts SW; van der Lely AJ; de Herder WW; Hofland LJ
    N Engl J Med; 1996 Jan; 334(4):246-54. PubMed ID: 8532003
    [No Abstract]   [Full Text] [Related]  

  • 15. Octreotide LAR in carcinoid: how to dose?
    Yao JC; Kvols LK
    Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of the somatostatin analogue octreotide acetate in the treatment of encephalopathy associated with carcinoid tumor. Case report.
    Siu LL; Chapman W; Moore MJ
    Am J Clin Oncol; 1997 Dec; 20(6):558-61. PubMed ID: 9391539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
    Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
    Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
    Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
    J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term octreotide treatment of metastatic carcinoid tumor.
    Corleto VD; Angeletti S; Schillaci O; Marignani M; Caratozzolo M; Panzuto F; Annibale B; Delle Fave G
    Ann Oncol; 2000 Apr; 11(4):491-3. PubMed ID: 10847473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
    Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
    Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.